Clinical Trial Update: Research Study to Look at How Well Semaglutide Works in People Living With Heart Failure, Obesity and Type 2 Diabetes [Phase 3]

View source ↗

Summary

Phase 3 trial update indicates the completion of a study evaluating semaglutide for heart failure with preserved ejection fraction and type 2 diabetes. Obesity …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure with Preserved Ejection Fraction
• Obesity
• Type 2 Diabetes Mellitus

Drugs mentioned

• semaglutide (semaglutide)

Snippet

Sponsor: Novo Nordisk A/S | Conditions: Heart Failure With Preserved Ejection Fraction (HFpEF) and Diabetes Mellitus, Type 2 | Phase 3 | Status: COMPLETED